United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening cardiovascular and infectious diseases and cancer. Our lead product, Remodulin, is approved in the U.S. and various countries around the world for both continuous subcutaneous and continuous intravenous infusion for the treatment of pulmonary arterial hypertension (PAH). In addition to prostacyclin analogs like Remodulin, United Therapeutics develops Glycobiological Antiviral Agents for the treatment of infectious diseases, such as Hepatitis C. For more information about United Therapeutics' pipeline, click here
To receive press releases, quarterly and annual SEC filings, please click here.
Jul 28, 2010
United Therapeutics Corporation Reports Second Quarter 2010 Financial Results
Sep 13, 2010
Morgan Stanley Global Healthcare Unplugged Conference
Nov 2, 2010
Oppenheimer 21st Annual Healthcare Conference